Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-10-21
Bispecific & Multispecific Antibodies Active Trials in China
As of 2026-10-21, there are 18 active clinical trials investigating Bispecific & Multispecific Antibodies for multiple myeloma across 30 provinces and 199 study centers in China. Bispecific antibodies redirect T cells to attack myeloma cells by concurrently binding CD3 and tumor surface targets (BCMA, GPRC5D, FcRH5) as off-the-shelf immunotherapies.
Active Trials
18
Provinces
30
Centers
199
Active Studies (18)
Population synthesized by CMDNShowing 17 published English records of 18 registry trials.
Phase ICTR20253656
RecruitingA Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Formulation of TQB2934 for Injection in Participants with Malignant Plasma Cell Neoplasms
Target Population: Relapsed/refractory
Target: Bispecific antibody targeting BCMA×CD3
Study Sites: Zhongshan Hospital, Fudan University、The Second Affiliated Hospital of Soochow University、The First Affiliated Hospital of Xi'an Jiaotong University、Nanjing Drum Tower Hospital 等 14 家中心
Clinical StudyCTR20250938
RecruitingELRANATAMAB Post-Trial Access: An Open-Label, Single-Arm Study for Multiple Myeloma Study Participants Continuing in Pfizer-Sponsored ELRANATAMAB Clinical Studies
Target Population: Multiple myeloma
Target: bispecific antibody
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Peking University Third Hospital、Shandong Provincial Hospital、Nanfang Hospital, Southern Medical University 等 7 家中心
Phase IIICTR20233883
RecruitingAn Open-Label, Two-Arm, Multicenter, Randomized, Phase III Study Evaluating the Efficacy and Safety of ELRANATAMAB (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Study Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible or Deferred Transplant
Target Population: Newly diagnosed/Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 17 家中心
Phase ICTR20241570
RecruitingA Multicenter, Open-label, Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of YKST02 in the Treatment of Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Harbin Medical University Cancer Hospital 等 13 家中心
Phase IIICTR20241434
RecruitingA Phase III, Randomized Study Comparing Teclistamab in Combination With Subcutaneous (SC) Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With SC Daratumumab and Lenalidomide (Tal-DR) Versus SC Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Not Eligible or Not Planned for Autologous Stem Cell Transplantation as Initial Therapy
Target Population: Newly diagnosed
Target: BCMA × CD3 bispecific antibody (MajestTEC-7 study)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、Sun Yat-sen University Cancer Center 等 32 家中心
Phase IIICTR20253381
RecruitingA Randomized, Controlled, Multicenter, Open-Label Phase III Study Evaluating the Efficacy and Safety of QLS32015 for Injection Monotherapy Versus Investigator's Choice of Regimen in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: GPRC5D/CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、First Affiliated Hospital of Kunming Medical University、Yunnan Cancer Hospital 等 82 家中心
Phase ICTR20242335
RecruitingAn Open-Label, Multicenter Phase I Clinical Study of SHR-9539 Injection Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Multiple Myeloma
Target Population: Multiple myeloma
Target: BCMA × CD3-targeting bispecific antibody
Study Sites: West China Hospital of Sichuan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Jiangxi Provincial People's Hospital 等 28 家中心
Phase I/IICTR20243384
RecruitingA Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Trispecific antibody targeting GPRC5D, BCMA, and CD3
Study Sites: Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University、The Affiliated Hospital of Xuzhou Medical University 等 23 家中心
Phase IICTR20250778
RecruitingAn Open-Label, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of F182112 in Combination with Different Dosing Regimens for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant Humanized Anti-BCMA/CD3 Bispecific Antibody for Injection
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Bengbu Medical University、The First Affiliated Hospital of Chongqing Medical University、Gansu Provincial Hospital 等 44 家中心
Phase ICTR20244043
RecruitingA Phase I Clinical Study Evaluating the Tolerability and Pharmacokinetics of TQB2029 for Injection in Participants with Multiple Myeloma
Target Population: Relapsed/refractory
Target: Bispecific antibody targeting GPRC5D×CD3
Study Sites: West China Hospital, Sichuan University、Zhongshan Hospital, Fudan University、Jiangsu Province Hospital、Anhui Provincial Hospital 等 12 家中心
Phase IICTR20252454
RecruitingA Multicenter, Open-label Phase II Study Evaluating QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Target Population: Multiple myeloma
Target: T-cell redirecting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、Nanyang Central Hospital、The First Affiliated Hospital of Zhengzhou University 等 50 家中心
Phase I/IICTR20232974
RecruitingA Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: GPRC5D × CD3 bispecific antibody
Study Sites: Peking University People's Hospital、The First Affiliated Hospital of Henan University of Science and Technology、Qingdao Municipal Hospital、Shenzhen Second People's Hospital 等 21 家中心
Phase IICTR20261752
RecruitingA Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Target Population: Multiple myeloma
Target: Trispecific antibody targeting BCMA, CD3, and GPRC5D
Study Sites: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Heze Municipal Hospital 等 39 家中心
Phase IbCTR20251016
RecruitingA Phase Ib, Open-Label, Single-Arm, Multicenter Study Evaluating the Pharmacokinetics, Safety, and Efficacy of CEVOSTAMAB in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: T-cell redirecting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Nanchang University、The First Affiliated Hospital of Wenzhou Medical University
Phase IIICTR20242452
RecruitingA Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Target Population: Relapsed/refractory
Target: BCMA × CD3 bispecific T-cell engager (BiTE)
Study Sites: The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center、Henan Cancer Hospital 等 19 家中心
Phase ICTR20232373
RecruitingA Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: GPRC5D × CD3-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University、The First Affiliated Hospital of Nanchang University 等 11 家中心
Phase ICTR20260125
RecruitingA Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant anti-BCMA and CD3 bispecific antibody injection
Study Sites: PKU Healthcare Luzhong Hospital